ProQR Therapeutics N.V. Business Summary

ProQR Therapeutics N.V. (PRQR) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing and collaboration agreements, most notably an expansive partnership with Eli Lilly and Company. The company operates as a single reportable segment focused on the discovery and development of RNA-based therapeutics using its proprietary Axiomer RNA editing technology, which harnesses endogenous ADAR enzymes to perform precise single-nucleotide edits. ProQR's financial model is underpinned by milestone-driven capital, including $4.5 million in payments achieved from Lilly in 2025, supporting a pipeline led by AX-0810 for cholestatic diseases and AX-2402 for Rett syndrome. Within the competitive landscape, ProQR contends with RNA and gene-editing firms such as Prime Medicine, MeiraGTx, Alnylam Pharmaceuticals, and CRISPR Therapeutics, positioning itself as a leader in the specialized niche of ADAR-mediated base editing rather than permanent DNA modification. The leadership team is led by Founding CEO Daniel A. de Boer, a serial entrepreneur who established the company in 2012, and Co-founder and Chief Scientific Officer Gerard Platenburg, a pioneer in RNA modulation formerly of Prosensa. In April 2025, the executive suite was further strengthened by the appointments of Chief Financial Officer Dennis Hom, who brought 25 years of experience from Sagimet Biosciences and Novartis, and Chief Medical Officer Dr. Cristina Lopez Lopez, previously the Global Head of Neurodegeneration at Johnson & Johnson. The company is governed by a board chaired by Dr. James Shannon, former CMO of GlaxoSmithKline, and has historically been backed by institutional investors like Sofinnova Partners. As of February 2026, the board is undergoing a strategic refresh following the planned departures of co-founder Dinko Valerio and director Alison Lawton to align with the company's transition into late-stage clinical development.